SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is trending after reporting blockbuster earnings and strong guidance, yet the stock's unexpectedly negative price action is sparking widespread frustration and claims of market manipulation, with the community debating whether this is a 'sell the news' event or a calculated effort to liquidate options.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending after reporting a profitable fourth quarter with raised 2026 revenue guidance, driven by new and expanded Material Transfer Agreements for its Matrix-M adjuvant, notably in oncology and with Pfizer. The community is actively discussing Matrix-M's broad potential, particularly in cancer vaccines, fueling speculation around a significant short squeeze or potential buyout amid increasing institutional ownership.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. It operates through the United States and International geographical segments. The firm offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

The Trade Desk is trending after its Q4 earnings beat was overshadowed by weaker-than-expected Q1 revenue and EBITDA guidance, leading to a significant stock plunge. The community is debating whether the sell-off is an overreaction and a buying opportunity given strong fundamentals, or if it reflects deeper concerns about increasing competition and the impact of AI in the ad-tech sector.

Eos Energy Enterprises, Inc. designs, manufactures, and deploys battery storage solutions for the electricity industry. It offers the Eos Znyth DC battery system product which designs to meet the requirements of the grid-scale energy storage market. The company was founded in 2008 and is headquartered in Edison, NJ.

Eos Energy Enterprises Inc - Ordinary Shares - Class A

Eos Energy Enterprises is trending following its Q4 earnings report, which, despite showing strong revenue growth, significantly missed analyst estimates and initiated lower-than-expected 2026 guidance. This has fueled widespread community frustration and questions about management's credibility, while some investors view the sharp decline as an overreaction and a buying opportunity in the burgeoning energy storage sector.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Celsius Holdings is trending after reporting strong earnings that surpassed market expectations, driven by significant growth in its Alani Nu brand. The community is energized, discussing the company's long-term potential for international expansion and expecting further analyst upgrades.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IonQ is trending following strong financial results that exceeded expectations, recent news of deploying a major quantum-secure network in Europe, and selection for a significant defense contract. These catalysts are driving bullish sentiment and calls for a short squeeze, despite ongoing community skepticism regarding the company's high valuation and profitability trajectory within the nascent quantum computing sector.

Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. It operates through the following segments: Teladoc Health Integrated Care, BetterHelp, and Others. The Teladoc Health Integrated Care segment offers virtual medical services. The BetterHelp segment includes virtual mental health and other wellness services. The company was founded in June 2002 by George Byron Brooks, Michael Gorton, and Gary Wald and is headquartered in New York, NY.

Teladoc Health Inc

Teladoc Health is actively discussed following its Q4 earnings report, which showcased positive free cash flow and international growth, alongside the extension of key Medicare telehealth flexibilities, leading the community to intensely debate its deep undervaluation and the prospects of a major short squeeze.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom is trending amid its ambitious projection to sell 1 million 3D-stacked AI chips by 2027 and the launch of a new 6G-class SoC, ahead of eagerly anticipated earnings expected to reveal significant AI revenue growth. The community remains largely bullish, buying dips despite price declines that many attribute to market manipulation, confident in the company's indispensable role in the expanding AI infrastructure.

Salesforce, Inc. engages in the design and development of cloud-based enterprise software for customer relationship management. Its solutions include sales force automation, customer service and support, marketing automation, digital commerce, community management, collaboration, industry-specific solutions, and salesforce platform. The firm also provides guidance, support, training, and advisory services. The company was founded by Marc Russell Benioff and Parker Harris in 1999 and is headquartered in San Francisco, CA.

Salesforce Inc

Salesforce (CRM) is trending following its Q4 earnings report, with community discussion centered on a massive $50 billion share buyback and increased dividend, which bulls see as a strong vote of confidence countering concerns about AI disruption and mixed guidance in the broader software sector.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is a hot topic following a Q4 earnings report and the announcement of CEO Doug Ingram's retirement, which has intensified debate among investors. The community is split, with some expressing deep frustration over the stock's persistent volatility and alleged short manipulation, while others are aggressively buying dips, confident in the company's undervalued commercial gene therapy and pipeline assets, especially amid international expansion.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Celldex Therapeutics (NASDAQ:CLDX) Receives Buy Rating from Stifel Nicolaus

Stifel Nicolaus reiterated a "buy" rating and set a $68.00 price objective (up from $58.00) on shares of Celldex Therapeutics in a research note on Thursday...

Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Average Recommendation of "Moderate Buy" by Brokerages

Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Get Free Report) have earned an average recommendation of "Moderate Buy" from the ten brokerages that are currently covering the company...

<ul class="summary-bullets"><li>The company now expects data from the program in the fourth quarter of 2026.&nbsp;</li><li>The program spans across 43 countries and over 500 sites and will evaluate the clinical effect of barzolvolimab in reducing urticaria activity at week 12.&nbsp;</li><li>The company plans to submit an application seeking approval for the therapy to the U.S. Food and Drug Administration in 2027.</li></ul>Shares of Celldex (CLDX) closed 24% higher on Wednesday after the company said that it has completed enrollment in a global late-stage program of Barzolvolimab in Chronic Spontaneous Urticaria ahead of schedule and data from it is now expected in the fourth quarter 2026.Overall, 1939 patients were enrolled in the program which includes two trials, the company said. The program spans across 43 countries and over 500 sites and will evaluate the clinical effect of barzolvolimab in reducing urticaria activity at week 12. &nbsp;“Completing enrollment in these large Phase 3 CSU studies 6 months ahead of guidance highlights the significant unmet need in CSU…” said CEO Anthony S. Marucci.<h2 class="st-heading-2">Trial Goal And Design</h2>The company plans to submit an application seeking approval for the therapy to the U.S. Food and Drug Administration in 2027 based on the data. The Phase 3 Program is designed to establish the efficacy and safety of barzolvolimab in adult patients with CSU who remain symptomatic despite H1 antihistamine treatment.Chronic spontaneous urticaria (CSU) is a skin condition characterized by itchy wheals (hives), angioedema (swelling), or both, occurring daily or almost daily for more than six weeks without an identifiable external trigger.As per data from the company’s mid-stage study of barzolvolimab in CSU, barzolvolimab has the potential to deliver symptom free complete control and dramatic improvements in quality of life and angioedema. Up to 51% of patients on the study had a complete response and were symptom free at 12 weeks.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around CLDX stock stayed within the ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.A Stocktwits user expressed optimism for the company’s market capitalization rising up to $25 billion on the strength of barzolvolimab’s annual sales. The user expects the drug’s sales to out perform Dupixent, a drug &nbsp;jointly developed and manufactured by Sanofi and Regeneron Pharmaceuticals, Inc.<stembedurl>https://www.stocktwits.com/free2dream/message/645895513</stembedurl>According to data from Koyfin, the average price target on CLDX is $53.36, representing a potential upside of about 73% from current trading levels. Of the 16 analysts covering the stock, 13 rate it ‘Buy’ or higher while two rate it ‘Hold’ and one rates it a ‘Strong Sell.’<a href="https://stocktwits.com/symbol/CLDX">CLDX stock</a> has risen over 48% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/syn-tsla-stocks-rise-on-reports-of-upcoming-govt-meeting-to-discuss-robotics-policies/cZRyiIbRIGq">SYM, TSLA Stocks Rise On Reports Of Upcoming Govt. Meeting To Discuss Robotics Policies</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Celldex Therapeutics logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

CLDX Soars On Bullish Timelines For Urticaria Clinical Program: Retail Sees Experimental Skin Treatment’s Sales Beat Big Pharma’s Dupixent 

The company said it has enrolled patients in its late-stage program ahead of schedule. 

Equity

The company said it has enrolled patients in its late-stage program ahead of schedule. 


Celldex Therapeutics (NASDAQ:CLDX) Sees Strong Trading Volume - Still a Buy?

Celldex Therapeutics (NASDAQ:CLDX) Sees Unusually-High Trading Volume - Here's Why...

Celldex Therapeutics (NASDAQ:CLDX) Trading 6.3% Higher - Still a Buy?

Celldex Therapeutics (NASDAQ:CLDX) Trading Up 6.3% - Still a Buy...

Readystate Asset Management LP Sells 288,480 Shares of Celldex Therapeutics, Inc. $CLDX

Readystate Asset Management LP trimmed its position in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 86.1% in the third quarter, according to the company in its most recent Form 13F...

Celldex Therapeutics (CLDX) Expected to Announce Earnings on Thursday

Celldex Therapeutics (NASDAQ:CLDX) will be releasing its Q4 2025 earnings before the market opens on Thursday, February 26. (View Earnings Report at...

Celldex Therapeutics Teases Key Barzolvolimab Phase 3 Updates, New Data at Guggenheim Summit

Celldex Therapeutics (NASDAQ:CLDX) executives used a presentation at the Guggenheim Emerging Outlook Biotech Summit 2026 to outline upcoming clinical milestones for barzolvolimab across multiple...

Celldex Therapeutics Breaks Below 200-Day Moving Average - Notable for CLDX

In trading on Thursday, shares of Celldex Therapeutics, Inc. (Symbol: CLDX) crossed below their 200 day moving average of $23.76, changing hands as low as $23.61 per share. Celldex Therapeutics, Inc...

Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the ten brokerages that are covering the company, MarketBeat.com...

Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	-$1.08	--	--	N/A
Q4 '25	-$1.01	-$1.22	-20.96%	MISSED
Q3 '25	-$0.90	-$1.01	-12.25%	MISSED
Q2 '25	-$0.86	-$0.85	0.68%	BEAT
Q1 '25	-$0.75	-$0.81	-7.29%	MISSED

CLDX
Celldex Therapeutics Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q4 '25

Historical Earnings

Latest CLDX News

CLDXCelldex Therapeutics Inc.